Publications in VIVO

Co-author Network

Eileen M Boyle, MD, MSc, PhD

Person

Positions

Consultant, University College London
Other, University College London

Clinical Disciplines

Hematology

Inflammation SIG

Publications
Other
View All

Selected Publications

article
1. Tumour-intrinsic features shape T cell differentiation through precursor to symptomatic multiple myeloma. NATURE COMMUNICATIONS. 2026
2. A proinflammatory response and polarized differentiation of stromal elements characterizes the murine myeloma bone marrow niche. EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2025
3. CAR-T cells co-targeting BCMA and CD19 in RRMM: Results from the UKMRA Phase 1 MCARTY trial in relapsed refractory multiple myeloma. BLOOD. 2025
4. Comparing Smouldering Myeloma High-Risk and Evolving Phenotype Definitions in the Prospective, Nationwide UK Cosmos Study. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2025
5. Current quality of life questionnaires are not relevant for assessing QOL issues in multiple myeloma patients in the era of modern therapies: results from a survey with myeloma patients and myeloma healthcare professionals. FRONTIERS IN ONCOLOGY. 2025
6. Double hit ultra-high risk myeloma treated with isatuximab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide (Isa-VRDc) induction and isa-VRD consolidation: Initial results of the UK myeloma research alliance (UKMRA) RADAR trial in newly diagnosed transplant eligible patients. BLOOD. 2025
7. Genomic landscape of multiple myeloma and its precursor conditions. NATURE GENETICS. 2025
8. Investigating the Role of the BAFF-APRIL System in Promoting Progression of Smouldering Myeloma (SMM). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2025
9. Long-read RNA sequencing of first multiple myeloma patient cohort reveals landscape of variant expression in newly diagnosed patients from the UKMRA RADAR trial. BLOOD. 2025
10. Monitoring and Management of CMV and other Viral Reactivations with Bispecific Antibodies (BsAbs) for Patients with Relapsed and Refractory Multiple Myeloma (RRMM). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2025
11. NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myeloma. BRITISH JOURNAL OF HAEMATOLOGY. 2025
12. Patient Perspectives of Receiving Out-patient Step-up Dosing with Bispecific Antibodies (BsAb) for Relapsed Multiple Myeloma (MM). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2025
13. The Role of Radiotherapy for Patients With Multiple Myeloma in the Modern Era: A Real World Single-Centre Experience. EJHAEM. 2025
14. A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data. BLOOD. 2024
15. Challenges in designing and running smouldering myeloma interventional clinical trials. eJHaem. 2024
16. Challenges in designing and running smouldering myeloma interventional clinical trials. EJHAEM. 2024
17. Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper. BRITISH JOURNAL OF HAEMATOLOGY. 2024
18. Evaluating Barriers to Enrolment into Multiple Myeloma (MM) Clinical Trials: Results from Health Care Professionals and Patient Survey from the UK Myeloma Research Alliance Equity, Diversity and Inclusivity (EDI) Working Group. BLOOD. 2024
19. Evolving Disease in Smouldering Myeloma (SMM) Is Accompanied by Serial Change in Immune Marrow Composition. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2024
20. Genomic Classification and Individualized Prognosis in Multiple Myeloma. JOURNAL OF CLINICAL ONCOLOGY. 2024
21. Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma. Clinical Cancer Research. 2024
22. Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma. CLINICAL CANCER RESEARCH. 2024
23. Inflammation and aging-related disease: A transdisciplinary inflammaging framework. GeroScience. 2024
24. Inflammation and aging-related disease: A transdisciplinary inflammaging framework. GEROSCIENCE. 2024
25. Longitudinal Analysis of t(11;14) and t(4;14) Genomes Reveals Distinct Evolutionary Trajectories in Multiple Myeloma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2024
26. Marrow Immune Features Are Most Informative of Early MRD Negative Treatment Response in Newly Diagnosed TE Patients: Insights from the UKMRA Phase 3 RADAR Study. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2024
27. Oral Symptom Assessment Using Patient Reported Outcomes (PRO) for Relapsed Multiple Myeloma Patients Treated with Talquetamab. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2024
28. Patient Perceptions When Receiving Talquetamab for Triple Class Exposed Relapsed/ Refractory Myeloma: A Thematic Analysis. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2024
29. Progression From Smouldering Myeloma to Myeloma Is Accompanied by an Increase in CD56bright Bone Marrow Resident NK Cells With Reduced NK Cell Cytotoxic Capacity. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2024
30. Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial. BLOOD. 2024
31. Study of T Cell Receptor (TCR) Dynamics in Smouldering Myeloma (SMM) Using TCR Sequence Clustering To Infer Contribution of the Immune Microenvironment to Progression to Multiple Myeloma (MM). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2024
32. Tumour-Intrinsic Features Shape T-Cell Differentiation through Myeloma Disease Evolution. BLOOD. 2024
33. Characterising risk and biology of smouldering myeloma for early detection of symptomatic myeloma: data from the UK cosmos study. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2023
34. Characterizing the landscape of rare structural variant events in newly diagnosed multiple myeloma. CANCER RESEARCH. 2023
35. Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myelome study. AMERICAN JOURNAL OF HEMATOLOGY. 2023
36. Comprehensive Genomic Characterization of Response and Resistance to Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma Patients. BLOOD. 2023
37. Comprehensive genomic characterization of response and resistance to daratumumab based quadruplet induction in newly diagnosed multiple myeloma patients. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2023
38. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens. NATURE CANCER. 2023
39. Impact of rare structural variant events in newly diagnosed multiple myeloma . bioRxiv. 2023
40. Individualized risk in newly diagnosed multiple myeloma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2023
41. Individualized risk stratification in newly diagnosed multiple myeloma. CANCER RESEARCH. 2023
42. Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma. Clinical Cancer Research. 2023
43. Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma. CLINICAL CANCER RESEARCH. 2023
44. Single Cell Analysis of Bone Marrow Stromal Cells Shows That a Pro-Inflammatory and Stress Response Together with Polarized Differentiation of Stromal Elements Characterize the Bone Marrow Microenvironment during Multiple Myeloma Development. BLOOD. 2023
45. Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients. BLOOD. 2023
46. The Cellular Impact, Immediate Targets and Mechanism of Action of NSD2 in t(4;14) Multiple Myeloma. BLOOD. 2023
47. The PANGEA model: catching the drift from precursor conditions to myeloma in individual patients. LANCET HAEMATOLOGY. 2023
48. Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures. Blood. 2023
49. Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures. BLOOD. 2023
50. Whole genome sequencing reveals significant genetic admixture in multiple myeloma patients, impacting assessment of etiology. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2023
51. Whole genome sequencing reveals significant genetic admixture in multiple myeloma patients, impacting assessment of etiology. CANCER RESEARCH. 2023
52. Bartonellosis mimicking post-transplant lymphoproliferative diseases. Nephrology Dialysis Transplantation. 2022
53. Bartonellosis mimicking post-transplant lymphoproliferative diseases. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2022
54. Chemotherapy Signatures Map Evolution of Therapy-Related Myeloid Neoplasms. bioRxiv. 2022
55. Chemotherapy signatures reveal the evolutionary history of post-melphalan myeloid neoplasm. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2022
56. Chemotherapy-related mutational signatures reveal the origins of therapy-related myeloid neoplasms. CANCER RESEARCH. 2022
57. Chemotherapy-related mutational signatures reveal the origins of therapy-related myeloid neoplasms.. CANCER RESEARCH. 2022
58. Chromothripsis as a pathogenic driver of multiple myeloma. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY. 2022
59. Extracellular Vesicles as Biomarkers of Acute Graft-vs.-Host Disease After Haploidentical Stem Cell Transplantation and Post-Transplant Cyclophosphamide. FRONTIERS IN IMMUNOLOGY. 2022
60. Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens. BLOOD. 2022
61. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. Nature Communications. 2022
62. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. NATURE COMMUNICATIONS. 2022
63. Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy. BLOOD. 2022
64. Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2022
65. Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma. BLOOD. 2022
66. Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length. LEUKEMIA. 2022
67. Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma. BLOOD. 2022
68. Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients. LEUKEMIA. 2022
69. Multiparameter flow cytometry in plasma cell disorders: when in doubt, go with the flow. British Journal of Haematology. 2022
70. Multiparameter flow cytometry in plasma cell disorders: when in doubt, go with the flow. BRITISH JOURNAL OF HAEMATOLOGY. 2022
71. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood Cancer Discovery. 2022
72. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. BLOOD CANCER DISCOVERY. 2022
73. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. LEUKEMIA. 2022
74. Structural Heterogeneity of Chromosome 1q Drives Outcome in Newly Diagnoses Myeloma. BLOOD. 2022
75. Structural variants shape the genomic landscape and clinical outcome of multiple myeloma. Blood Cancer Journal. 2022
76. Structural variants shape the genomic landscape and clinical outcome of multiple myeloma. BLOOD CANCER JOURNAL. 2022
77. The Mutagenic Impact of Radiotherapy in Multiple Myeloma. BLOOD. 2022
78. Tracking the Earliest Genomic Events in Multiple Myeloma Life-History. BLOOD. 2022
79. Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures. BLOOD. 2022
80. Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin. BLOOD. 2022
81. A proof-of-concept study for the pathogenetic role of enhancer hypomethylation of MYBPHL in multiple myeloma. SCIENTIFIC REPORTS. 2021
82. Accelerated single cell seeding in relapsed multiple myeloma (vol 11, 3617, 2020). NATURE COMMUNICATIONS. 2021
83. Case Report: Two Cases of Cryptosporidiosis in Heavily Pretreated Patients With Myeloma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2021
84. Case Report: Two Cases of Cryptosporidiosis in Heavily Pretreated Patients With Myeloma.. Clinical lymphoma, myeloma & leukemia. 2021
85. Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms. BLOOD. 2021
86. Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma. NATURE COMMUNICATIONS. 2021
87. Differential RNA splicing as a potentially important driver mechanism in multiple myeloma. HAEMATOLOGICA. 2021
88. Differential RNA splicing as a potentially important driver mechanism in multiple myeloma.. Haematologica. 2021
89. From Bench to Bedside The Evolution of Genomics and Its Implications for the Current and Future Management of Multiple Myeloma. CANCER JOURNAL. 2021
90. Genetic Subtypes of Smoldering Multiple Myeloma are associated with Distinct Pathogenic Phenotypes and Clinical Outcomes. bioRxiv. 2021
91. Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes. BLOOD. 2021
92. Genomic and Immune Signatures Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (D-KRd). BLOOD. 2021
93. High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. BRITISH JOURNAL OF HAEMATOLOGY. 2021
94. High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. British Journal of Haematology. 2021
95. Hispanic or Latin American Ancestry Is Associated with a Similar Genomic Profile and a Trend Toward Inferior Outcomes in Newly Diagnosed Multiple Myeloma As Compared to Non-Hispanic White Patients in the Multiple Myeloma Research Foundation (MMRF) CoMMpassstudy. BLOOD. 2021
96. Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length. Leukemia. 2021
97. Improving prognostic assignment in older age groups of multiple myeloma. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY. 2021
98. Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2021
99. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA. EUROPEAN JOURNAL OF HAEMATOLOGY. 2021
100. Multiomic Mapping of Copy Number and Structural Variation on Chromosome 1 (Chr1) Highlights Multiple Recurrent Disease Drivers. BLOOD. 2021
101. PHF19 inhibition as a therapeutic target in multiple myeloma. CURRENT RESEARCH IN TRANSLATIONAL MEDICINE. 2021
102. PHF19 inhibition as a therapeutic target in multiple myeloma. Current Research in Translational Medicine. 2021
103. The evolving role and utility of off-label drug use in multiple myeloma. Exploration of Targeted Anti-tumor Therapy. 2021
104. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. NATURE COMMUNICATIONS. 2021
105. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma.. Nature communications. 2021
106. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). EUROPEAN JOURNAL OF HAEMATOLOGY. 2021
107. Unifying the Definition of High-Risk in Multiple Myeloma. BLOOD. 2021
108. BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. CLINICAL CANCER RESEARCH. 2020
109. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. BLOOD. 2020
110. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. LEUKEMIA. 2020
111. Accelerated single cell seeding in relapsed multiple myeloma. NATURE COMMUNICATIONS. 2020
112. Accelerated single cell seeding in relapsed multiple myeloma.. Nature communications. 2020
113. Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size.. Leukemia research reports. 2020
114. BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical Cancer Research. 2020
115. Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population. BRITISH JOURNAL OF HAEMATOLOGY. 2020
116. Deep sequencing as an approach to understanding the complexity and improving the treatment of multiple myeloma. EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT. 2020
117. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. BLOOD CANCER JOURNAL. 2020
118. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns.. Blood cancer journal. 2020
119. Impact of Etiological Cytogenetic Abnormalities on Immunoparesis and Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma. BLOOD. 2020
120. Influence of Aging Processes on the Biology and Outcome of Multiple Myeloma. BLOOD. 2020
121. Management and outcome of primary CNS lymphoma in the modern era An LOC network study. NEUROLOGY. 2020
122. Monitoring minimal residual disease in the bone marrow using next generation sequencing. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY. 2020
123. Monitoring minimal residual disease in the bone marrow using next generation sequencing.. Best practice & research. Clinical haematology. 2020
124. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA.. European journal of haematology. 2020
125. Reconstructing the evolutionary history of multiple myeloma. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY. 2020
126. Reconstructing the evolutionary history of multiple myeloma.. Best practice & research. Clinical haematology. 2020
127. Revealing the Impact of Structural Variants in Multiple Myeloma. BLOOD CANCER DISCOVERY. 2020
128. Revealing the Impact of Structural Variants in Multiple Myeloma. Blood Cancer Discovery. 2020
129. Revealing the impact of structural variants in multiple myeloma.. Blood cancer discovery. 2020
130. TarPan: an easily adaptable targeted sequencing panel viewer for research and clinical use. BMC BIOINFORMATICS. 2020
131. TarPan: an easily adaptable targeted sequencing panel viewer for research and clinical use.. BMC bioinformatics. 2020
132. Treatment with Temozolomide and Ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL). BLOOD. 2020
133. A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study. NEURO-ONCOLOGY. 2019
134. Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma. BLOOD. 2019
135. Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. AMERICAN JOURNAL OF HEMATOLOGY. 2019
136. Chromoplexy and Chromothripsis Are Important Prognostically in Myeloma and Deregulate Gene Function By a Range of Mechanisms. BLOOD. 2019
137. Circulating cell free DNA is a biomarker for GEP70 risk score and tumor burden in myeloma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019
138. Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial. BRITISH JOURNAL OF HAEMATOLOGY. 2019
139. Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial. British Journal of Haematology. 2019
140. Enrichment for copy number alterations and a unique pattern of gene mutations characterize multiple myeloma in elderly patients. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019
141. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. LEUKEMIA. 2019
142. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.. Leukemia. 2019
143. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. EUROPEAN JOURNAL OF CANCER. 2019
144. Long-term Analysis Of Multiple Sequential Samples Reveals Patterns Of Progression In Smoldering Myeloma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019
145. POEMS syndrome. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE. 2019
146. Revealing the impact of recurrent and rare structural variants in multiple myeloma. bioRxiv. 2019
147. The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma. BLOOD. 2019
148. The Spectrum of Exomic Mutation in Elderly Myeloma Differs Substantially from Patients at Younger Ages Consistent with a Different Evolutionary Trajectory to Full Blown Disease Based on Age of Onset. BLOOD. 2019
149. Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03). BLOOD. 2019
150. A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. LEUKEMIA. 2018
151. Acute polyradiculopathy secondary to idelalisib in Relapsed Classical Hodgkin's lymphoma. CURRENT RESEARCH IN TRANSLATIONAL MEDICINE. 2018
152. Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. 2018
153. Efficacy and Safety of Daratumumab in a Frail Real-Life Relapsed or Refractory Systemic Light-Chain Amyloidosis Population (AL): Report on 15 Cases from the North of France. BLOOD. 2018
154. Evaluation of the Relevance of Surgery in Patients with Multiple Myeloma Harboring Symptomatic Spinal Involvement: A Retrospective Case Series. WORLD NEUROSURGERY. 2018
155. Evaluation of the Relevance of Surgery in Patients with Multiple Myeloma Harboring Symptomatic Spinal Involvement: A Retrospective Case Series. World Neurosurgery. 2018
156. Extracting Prognostic Molecular Information from PF:T-CT Imaging of Multiple Myeloma Using Radiomic Approaches. BLOOD. 2018
157. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. BLOOD. 2018
158. Heavy plus light chain analysis to assign myeloma response is analogous to the IMWG response criteria. LEUKEMIA & LYMPHOMA. 2018
159. Intratubular amyloid in light chain cast nephropathy is a risk factor for systemic light chain amyloidosis. MODERN PATHOLOGY. 2018
160. Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma. BLOOD. 2018
161. Mutations and Copy Number Changes Predict Progression from Smoldering Myeloma to Symptomatic Myeloma in the Era of Novel IMWG Criteria. BLOOD. 2018
162. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. LEUKEMIA. 2018
163. The Mutational Landscape of Primary Plasma Cell Leukemia. BLOOD. 2018
164. The genomic landscape of plasma cells in systemic light chain amyloidosis. BLOOD. 2018
165. The genomic landscape of plasma cells in systemic light chain amyloidosis. Blood. 2018
166. Treatment of Elderly Patients with Multiple Myeloma. MULTIPLE MYELOMA AND OTHER PLASMA CELL NEOPLASMS. 2018
167. BACH2 promotes indolent clinical presentation in Waldenstrom macroglobulinemia. ONCOTARGET. 2017
168. A Prospective Phase II of Daratumumab in Previously-Treated Systemic Light-Chain (AL) Amyloidosis. BLOOD. 2017
169. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. BLOOD. 2017
170. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.. Blood. 2017
171. Expressed fusion gene landscape and its impact in multiple myeloma. NATURE COMMUNICATIONS. 2017
172. Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria.. Leukemia & lymphoma. 2017
173. IBRUTINIB MONOTHERAPY IN RELAPSED/REFRACTORY CNS LYMPHOMA: A RETROSPECTIVE CASE SERIES. NEUROLOGY. 2017
174. Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series.. Neurology. 2017
175. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.. Leukemia. 2017
176. Role of IRF4 in resistance to immunomodulatory (IMid) compounds® in Waldenstrom's macroglobulinemia. ONCOTARGET. 2017
177. Somatic mutation spectrum in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape compared to multiple myeloma.. Haematologica. 2017
178. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. HAEMATOLOGICA. 2017
179. Treating Clostridium difficile infection in patients presenting with hematological malignancies: Are current guidelines applicable?. MEDECINE ET MALADIES INFECTIEUSES. 2017
180. A FRAILTY SCALE PREDICTS OUTCOMES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH CONTINUOUS LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN THE FIRST (MM-020) TRIAL. HAEMATOLOGICA. 2016
181. BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia.. Oncotarget. 2016
182. DEVELOPMENT OF A PREDICTIVE MODEL TO IDENTIFY PATIENTS WITH MULTIPLE MYELOMA NOT ELIGIBLE FOR AUTOLOGOUS TRANSPLANT AT RISK FOR SEVERE INFECTIONS USING DATA FROM THE FIRST TRIAL. HAEMATOLOGICA. 2016
183. Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial. BLOOD. 2016
184. Genomic Landscape of CXCR4 Mutations in Waldenstrom Macroglobulinemia. CLINICAL CANCER RESEARCH. 2016
185. Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016
186. Ibrutinib Monotherapy in Relapse or Refractory Primary CNS Lymphoma (PCNSL) and Primary Vitreo-Retinal Lymphoma (PVRL). Result of the Interim Analysis of the iLOC Phase II Study from the Lysa and the French LOC Network. BLOOD. 2016
187. IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenstrom's Macroglobulinaemia. CLINICAL CANCER RESEARCH. 2016
188. IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016
189. POST-INDUCTION MINIMAL RESIDUAL DISEASE ASSESSMENT BY BOTH MULTIPARAMETER FLOW CYTOMETRY AND RT-PCR PREDICTS OUTCOME IN ACUTE MYELOID LEUKEMIA. HAEMATOLOGICA. 2016
190. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. BLOOD. 2016
191. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.. Blood. 2016
192. The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. CLINICAL CANCER RESEARCH. 2016
193. The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016
194. A Molecular Diagnostic Approach Able to Detect the Recurrent Genetic Prognostic Factors Typical of Presenting Myeloma. GENES CHROMOSOMES & CANCER. 2015
195. A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma.. Genes, chromosomes & cancer. 2015
196. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. NATURE COMMUNICATIONS. 2015
197. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.. Nature communications. 2015
198. Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma. BRITISH JOURNAL OF HAEMATOLOGY. 2015
199. Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma.. British journal of haematology. 2015
200. Can Assessment of Patient Monoclonal Immunoglobulins By Heavy/Light Analysis be Used to Assign Patient Responses Analogous to IMWG Response Criteria?. BLOOD. 2015
201. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. BLOOD. 2015
202. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.. Blood. 2015
203. EXOME SEQUENCING POINTS TO DIFFERENCES IN GENETIC INSTABILITY LEVEL IN MGUS COMPARED TO MM. HAEMATOLOGICA. 2015
204. Exome sequencing and SNP arrays as a tool to describe genetic diversity of premalignant and malignant cells: lesson from monoclonal gammopathies. CHROMOSOME RESEARCH. 2015
205. Impact of Anti-CD20 Antibodies on the Incidence of Secondary Cancers in Patients Treated for Chronic Lymphocytic Leukemia. BLOOD. 2015
206. Impact of Poor Tolerance and Discontinuation of the Dexamethasone during Treatment with Lenalidomide-Dexamethasone in Relapsed and Refractory Multiple Myeloma. BLOOD. 2015
207. Molecular Subgroups of Hyperdiploidy and Their Prognostic Relevance - an Analysis of 1,036 Myeloma Trial Patients. BLOOD. 2015
208. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. JOURNAL OF CLINICAL ONCOLOGY. 2015
209. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015
210. Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TC. BLOOD. 2015
211. Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma. EXPERT OPINION ON DRUG SAFETY. 2015
212. Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma.. Expert opinion on drug safety. 2015
213. Retrospective observational study of patients with relapsed/refractory myeloma treated with pomalidomide - the UK Experience. BRITISH JOURNAL OF HAEMATOLOGY. 2015
214. Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing. BLOOD. 2015
215. Specific Identification of High Risk Disease Using Molecular Profiling By Mymap (Myeloma MLPA and translocation PCR) of 1,036 Cases. BLOOD. 2015
216. MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome. BRITISH JOURNAL OF HAEMATOLOGY. 2014
217. Postpartum acute renal failure: a multicenter study of risk factors in patients admitted to ICU. ANNALS OF INTENSIVE CARE. 2014
218. Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma. BLOOD. 2014
219. B-cell malignancies: capture-sequencing strategies for identification of gene rearrangements and translocations into immunoglobulin gene loci. BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY. 2014
220. Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors. CANCER CELL. 2014
221. Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors (vol 26, pg 495, 2014). CANCER CELL. 2014
222. Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors.. Cancer cell. 2014
223. Characterization of RAS Alterations in Myeloma: Why Direct Targeting of RAS May be the Most Appropriate Therapeutic Approach. BLOOD. 2014
224. Comparison of Waldenstrom Macroglobulinemia Responses Using Immunoglobulin Heavy / Light Chain Analysis and Conventional Electrophoresis Techniques. BLOOD. 2014
225. Exome Sequencing to Define a Genetic Signature of Plasma Cells in Systemic AL Amyloidosis. BLOOD. 2014
226. High Resolution Genome Wide DNA Methylation Analysis in a Large Trial Group Reveals a Novel Epigenetically Defined Subgroup of Myeloma Patients Characterized By Developmental Gene Hypermethylation. BLOOD. 2014
227. High Throughput Genetic Profiling Using a Robust All-Molecular Diagnostic Approach Is Feasible to Specifically Identify a High Risk Group of Myeloma Patients. BLOOD. 2014
228. IgA Kappa/IgA Lambda Heavy/Light Chain Assessment in the Management of Patients With IgA Myeloma. CANCER. 2014
229. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.. Cancer. 2014
230. MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome.. British journal of haematology. 2014
231. Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients. BLOOD. 2014
232. Rapid, Robust and Accessible Molecular Profiling of Biologically and Clinically Relevant Copy Number Alterations in Multiple Myeloma from Small Amounts of Tumor DNA. BLOOD. 2014
233. Somatic Mutation Spectrum in Monoclonal Gammopathy of Undetermined Significance Compared to Multiple Myeloma. BLOOD. 2014
234. The Extent of Intra-Clonal Genetic Diversity within the Myeloma Clone Is a Predictive Biomarker of Progression and Outcome after Treatment. BLOOD. 2014
235. The Spectrum of Epigenetic Mutations in Myeloma and Their Clinical Impact. BLOOD. 2014
236. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. BLOOD CANCER JOURNAL. 2014
237. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients.. Blood cancer journal. 2014
238. Understanding the multiple biological aspects leading to myeloma. HAEMATOLOGICA. 2014
239. Understanding the multiple biological aspects leading to myeloma.. Haematologica. 2014
240. Co-Existent Hyperdiploidy Does Not Abrogate The Poor Prognosis Associated With Adverse Cytogenetics In Myeloma. BLOOD. 2013
241. Exome Sequencing To Define A Genetic Signature Of Plasma Cells In Systemic AL Amyloidosis. BLOOD. 2013
242. Genomic Studies Have Identified Multiple Mechanisms of Genetic Changes in Waldenstrom Macroglobulinemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2013
243. Genomic studies have identified multiple mechanisms of genetic changes in Waldenström macroglobulinemia.. Clinical lymphoma, myeloma & leukemia. 2013
244. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. THROMBOSIS AND HAEMOSTASIS. 2013
245. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs.. Thrombosis and haemostasis. 2013
246. Myeloma, IMiDs and thrombosis. HEMATOLOGIE. 2013
247. The Value Of Serum Free Light Chain Monitoring Compared To Urinary Bence-Jones Measurement In Light Chain Only Myeloma. BLOOD. 2013
248. B-Cell-Specific Transcription Factor BACH2 Involved in the Clinical Behavior Heterogeneity of Waldenstrom Macroglobulinemia. BLOOD. 2012
249. Cast nephropathy with light-chain disease in low grade lymphoplasmacytic lymphoma/Waldenstrm macroglobulinemia. HEMATOLOGIE. 2012
250. Early Human Herpesvirus Type 6 Reactivation after Allogeneic Stem Cell Transplantation: A Large-Scale Clinical Study. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 2012
251. Early coagulopathy in trauma patients: An on-scene and hospital admission study. INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED. 2012
252. Early coagulopathy in trauma patients: an on-scene and hospital admission study.. Injury. 2012
253. Early human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2012
254. Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis. EXPERT REVIEW OF HEMATOLOGY. 2012
255. Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis.. Expert review of hematology. 2012
256. Prognostic value of PINI index in patients with multiple myeloma. EUROPEAN JOURNAL OF HAEMATOLOGY. 2012
257. Prognostic value of PINI index in patients with multiple myeloma.. European journal of haematology. 2012
258. Residents and ICU nurses get reliable static and dynamic haemodynamic assessments with aortic oesophageal Doppler. ACTA ANAESTHESIOLOGICA SCANDINAVICA. 2012
259. Advances in maintenance treatment in multiple myeloma: the place of immunomodulators (IMiDs). ONCOLOGIE. 2011
260. Hevylite, a Novel M-Component Based Biomarkers of Response to Therapy and Survival in Waldenstrom Macroglobulinemia. BLOOD. 2011
261. Novel M-Component Based Biomarkers in Waldenstrom's Macroglobulinemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2011
262. Novel M-component based biomarkers in Waldenström's macroglobulinemia.. Clinical lymphoma, myeloma & leukemia. 2011
263. Ongoing Development of Monoclonal Antibodies and Antibody Drug-Conjugates in Lymphoma. CURRENT ONCOLOGY REPORTS. 2011
264. Ongoing development of monoclonal antibodies and antibody drug-conjugates in lymphoma.. Current oncology reports. 2011
265. Risk Factors of Thromboembolic Events in Multiple Myeloma Treated with IMiDs-Based Therapy While on LMWH Prophylaxis. BLOOD. 2011
266. The EDS® System for the Detection of Bone Lesions in Patients with Multiple Myeloma. BLOOD. 2011
document